VICPLAS INTERNATIONAL LTD (569) Fair Value & Analysis
Healthcare · SG · Market cap 37.8M SGD
Fair value as of: Aug 13, 2026
From 2 valuation models · updated 4 days ago
Fair value updated Aug 13, 2026, revised from 0.0638 SGD to 0.0630 SGD (−1.2%) since Aug 8, 2026. Share price +9.6% over the past month.
A solid business, but screening 21% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (0.0770 SGD). The favourable scenario is already priced in.
- Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 0.0700 SGD – 0.2500 SGD · fair‑value band 0.0490 SGD – 0.0770 SGD · the 0.0800 SGD price screens above the 0.0630 SGD fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
VICPLAS INTERNATIONAL LTD (569) currently trades at 0.0800 SGD, while our model-based Fair Value estimate is 0.0630 SGD, implying the stock looks roughly 21.3% overvalued today. The Quality Score stands at 50/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, VICPLAS INTERNATIONAL LTD generated revenue of 128M SGD at a net margin of -4.7%. Revenue grew 13.1% year over year. It earns a return on equity of -8.4%. Net debt stands at 14.0M SGD. Fundamentals as of Aug 13, 2026
Our scenario range runs from 0.0490 SGD (bear case) to 0.0770 SGD (bull case); at 0.0800 SGD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 21% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at -21%, 569 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 2 models by family
Widest divergence: Multiples (0.1000 SGD) versus Multiples (0.1000 SGD). Highest evidence: EV/EBITDA (54).
Notify me when 569 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 53 · Market factors (momentum, volatility) 40
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Vicplas International Ltd, an investment holding company, engages in the medical devices, and pipes and pipe fittings businesses in Singapore, Malaysia, the People's Republic of China, the United Kingdom, and Mexico.
Full company description
Vicplas International Ltd, an investment holding company, engages in the medical devices, and pipes and pipe fittings businesses in Singapore, Malaysia, the People's Republic of China, the United Kingdom, and Mexico. The company manufactures, trades, and distributes piping systems for various industries, including waste and potable water systems for residential homes, schools, and commercial and industrial buildings; underground electrical and internal building wire piping systems; and data and signal line piping systems by telecommunications companies. It also designs, develops, manufactures, and assembles sterile and non-sterile medical devices. Vicplas International Ltd was founded in 1993 and is based in Singapore. Vicplas International Ltd is a subsidiary of Venner Capital S.A.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
VICPLAS INTERNATIONAL LTD reported revenue of 102M SGD in FY2024 versus 88.8M SGD in FY2020, a compound +3.6%/yr. Reported net income was −1.4M SGD in FY2024.
569 screens 21% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 353 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.60 | ¥147.63 | -4% |
| Shanghai United Imaging Healthcare Co 688271 | ¥110.50 | ¥43.60 | -61% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 239.30 | kr 192.14 | -20% |
| Sectra AB SECTB | kr 280.00 | kr 66.81 | -76% |
Compare VICPLAS INTERNATIONAL LTD with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is VICPLAS INTERNATIONAL LTD (569) overvalued or undervalued?
What is the fair value of 569?
What is the quality score of 569?
What is the revenue of VICPLAS INTERNATIONAL LTD (569)?
What is the net profit margin of 569?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track VICPLAS INTERNATIONAL LTD and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.